ALXN News and Press, Alexion Pharmaceuticals Inc. From 05/11/21

Alexion Pharmaceuticals ([[ALXN]] -0.6%) shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca.The acquisition is expected to close in Q3 2021.Press Release For further details see: Alexion shareholders approve acquisition by ...

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca at a special meeting of shareholders held today. Ludwig Hantson, Ph.D., Chief Executive Officer, Ale...

Alexion's (ALXN) was upgraded to outperform as the current deal to sell itself to AstraZeneca (AZN) for about $39B appears "too cheap," according to Oppenheimer."With the recent near-term business strength, a strong case for >$10B in revenues by FY25 and a surprisingly full pipeline, ...

AstraZeneca (AZN) is said not to expect to see antitrust issues for its planned purchase of Alexion (ALXN) in the geographies where the deal is still being approved.Filings with the European Commission and the UK Competition and Markets Authority (CMA) aren't expected to raise competitio...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Value and recovery stocks have started to climb and shoul...

These Biotech Stocks Have Gained Investors’ Attention So Far This Week. When it comes to high-risk, high-reward investments in the stock market, biotech stocks come to mind. The biotech industry has been notorious for its performance being predicated on its success of cli...

Top-rated stocks in our research that also have a strong track record of beating analyst expectations. Stock ideas cutting across most sectors. Over 50 ideas worth considering for watch lists. For further details see: Stocks With The Best History Of Beating Estimates

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Alexion Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation

Alexion Pharmaceuticals (ALXN) shares rise more than 2% during premarket trading as the company posted first-quarter results that beat Wall Street estimates.The company's quarterly revenue increased 14% to $1.64B, compared to analyst' estimate of $1.58B.Net product sales were $1,636...

Alexion Pharmaceuticals (ALXN): Q1 Non-GAAP EPS of $3.52 beats by $0.38; GAAP EPS of $2.86 beats by $0.30.Revenue of $1.64B (+13.9% Y/Y) beats by $60M.Shares +2.3% PM.Press Release For further details see: Alexion Pharmaceuticals EPS beats by $0.38, beats on revenue